Pharmaceutical

Atsena closes $150m in Series C round to progress gene therapy

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ATSN-201.

Apr 4, 2025 - 06:00
Atsena closes $150m in Series C round to progress gene therapy
Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ATSN-201.
Read the original article

Tags:

Previous Article

ABPI calls on UK Government to resolve “VPAG crisis”

Next Article

IO360 summit: CAR-T cell therapy applications beyond blood cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan...

Oct 20, 2024

BIOSECURE “grandfather” amendment softens impact of US-China trade ban

BIOSECURE “grandfather” amendment softens impact of US-...

May 31, 2024

Novo Holdings completes Catalent acquisition for $16.5bn

Novo Holdings completes Catalent acquisition for $16.5bn

Dec 19, 2024